<?xml version="1.0" encoding="UTF-8"?>

<BioModel name="CM_PM19804630_MB2::Erk_activation">
  <url name="MolecularType(PP2A)">http://identifiers.org/obo.go:GO%3A0000159</url>
  <url name="MolecularType(ERK)">http://identifiers.org/uniprot:P21708</url>
  <url name="MolecularType(ERK)">http://identifiers.org/uniprot:P63086</url>
  <url name="MolecularType(MEK)">http://identifiers.org/uniprot:P36506</url>
  <url name="MolecularType(MEK)">http://identifiers.org/uniprot:Q01986</url>
  <url name="MolecularType(MEK)">http://identifiers.org/doid/DOID:162</url>
  <url name="MolecularType(MEK)">http://identifiers.org/taxonomy/10116</url>
  <url name="MolecularType(MEK)">http://identifiers.org/obo.go:GO%3A0000165</url>
  <url name="MolecularType(MEK)">http://identifiers.org/go/GO:0007173</url>
  <url name="MolecularType(MEK)">http://identifiers.org/bto/BTO:0001009</url>
  <url name="MolecularType(MEK)">http://identifiers.org/biomodels.db/MODEL1611280000</url>
  <url name="MolecularType(MEK)">http://identifiers.org/biomodels.db/BIOMD0000000623</url>
  <url name="MolecularType(MEK)">http://identifiers.org/biomodels.db/BIOMD0000000033</url>
  <url name="MolecularType(MEK)">http://identifiers.org/pubmed/19804630</url>
  <url name="MolecularType(MEK)">http://identifiers.org/go/GO:0005623</url>
  <url name="MolecularType(MEK)">http://identifiers.org/uniprot/P36506</url>
  <url name="MolecularType(MEK)">http://identifiers.org/uniprot/Q01986</url>
  <url name="MolecularType(MEK)">http://identifiers.org/uniprot/Q01986</url>
  <url name="MolecularType(MEK)">http://identifiers.org/uniprot/P36506</url>
  <url name="MolecularType(MEK)">http://identifiers.org/uniprot/P63086</url>
  <url name="MolecularType(MEK)">http://identifiers.org/uniprot/P21708</url>
  <url name="MolecularType(MEK)">http://identifiers.org/uniprot/P21708</url>
  <url name="MolecularType(MEK)">http://identifiers.org/uniprot/P63086</url>
  <url name="MolecularType(MEK)">http://identifiers.org/uniprot/Q9Z1I2</url>
  <url name="MolecularType(MEK)">http://identifiers.org/uniprot/Q63531</url>
  <url name="MolecularType(MEK)">http://identifiers.org/uniprot/Q9Z1I2</url>
  <url name="MolecularType(MEK)">http://identifiers.org/uniprot/Q63531</url>
  <url name="MolecularType(MEK)">http://identifiers.org/uniprot/Q63787</url>
  <url name="MolecularType(MEK)">http://identifiers.org/uniprot/Q63787</url>
  <url name="MolecularType(MEK)">http://identifiers.org/uniprot/P47196</url>
  <url name="MolecularType(MEK)">http://identifiers.org/uniprot/P47197</url>
  <url name="MolecularType(MEK)">http://identifiers.org/uniprot/Q63484</url>
  <url name="MolecularType(MEK)">http://identifiers.org/uniprot/Q63484</url>
  <url name="MolecularType(MEK)">http://identifiers.org/uniprot/P47197</url>
  <url name="MolecularType(MEK)">http://identifiers.org/uniprot/P47196</url>
  <url name="MolecularType(MEK)">http://identifiers.org/uniprot/Q9QX70</url>
  <url name="MolecularType(MEK)">http://identifiers.org/chebi:74440</url>
  <url name="MolecularType(MEK)">http://identifiers.org/uniprot/Q9QX70</url>
  <url name="MolecularType(MEK)">http://identifiers.org/uniprot/Q9QYV3</url>
  <url name="MolecularType(MEK)">http://identifiers.org/uniprot/Q9QYV3</url>
  <url name="MolecularType(MEK)">http://identifiers.org/uniprot/Q62636</url>
  <url name="MolecularType(MEK)">http://identifiers.org/uniprot/Q62636</url>
  <url name="MolecularType(MEK)">http://identifiers.org/uniprot/F1M9C3</url>
  <url name="MolecularType(MEK)">http://identifiers.org/uniprot/F1M9C3</url>
  <url name="MolecularType(MEK)">http://identifiers.org/uniprot/P07522</url>
  <url name="MolecularType(MEK)">http://identifiers.org/go/GO:0000159</url>
  <url name="MolecularType(MEK)">http://identifiers.org/go/GO:1903293</url>
  <url name="MolecularType(MEK)">http://identifiers.org/uniprot/Q9QX70</url>
  <url name="MolecularType(MEK)">http://identifiers.org/uniprot/P50904</url>
  <url name="MolecularType(MEK)">http://identifiers.org/uniprot/F1LV89</url>
  <url name="MolecularType(MEK)">http://identifiers.org/uniprot/Q9QX70</url>
  <url name="MolecularType(MEK)">http://identifiers.org/sbo/SBO:0000012</url>
  <url name="MolecularType(MEK)">http://identifiers.org/sbo/SBO:0000029</url>
  <url name="MolecularType(MEK)">http://identifiers.org/sbo/SBO:0000012</url>
  <url name="MolecularType(MEK)">http://identifiers.org/sbo/SBO:0000029</url>
  <url name="MolecularType(MEK)">http://identifiers.org/sbo/SBO:0000029</url>
  <url name="MolecularType(MEK)">http://identifiers.org/sbo/SBO:0000029</url>
  <url name="MolecularType(MEK)">http://identifiers.org/sbo/SBO:0000029</url>
  <url name="MolecularType(MEK)">http://identifiers.org/uniprot/Q9Z1I1</url>
  <url name="MolecularType(MEK)">http://identifiers.org/sbo/SBO:0000029</url>
  <url name="MolecularType(MEK)">http://identifiers.org/sbo/SBO:0000029</url>
  <url name="MolecularType(MEK)">http://identifiers.org/obo.go:GO%3A0000187</url>
  <url name="MolecularType(MEK)">http://identifiers.org/pubmed:17496923</url>
  <url name="MolecularType(MEK)">http://identifiers.org/sbo:SBO%3A0000029</url>
  <url name="MolecularType(MEK)">http://identifiers.org/obo.go:GO%3A0000188</url>
  <url name="MolecularType(MEK)">http://identifiers.org/sbo/SBO:0000029</url>
  <url name="MolecularType(MEK)">http://identifiers.org/pubmed:32759757</url>
  <url name="MolecularType(MEK)">http://identifiers.org/sbo/SBO:0000029</url>
  <url name="MolecularType(MEK)">http://identifiers.org/sbo/SBO:0000012</url>
  <url name="MolecularType(MEK)">http://identifiers.org/sbo/SBO:0000029</url>
  <url name="MolecularType(MEK)">http://identifiers.org/sbo/SBO:0000029</url>
  <url name="MolecularType(MEK)">http://identifiers.org/sbo/SBO:0000029</url>
  <url name="MolecularType(MEK)">http://identifiers.org/sbo/SBO:0000012</url>
  <url name="MolecularType(MEK)">http://identifiers.org/uniprot/Q9Z1I1</url>
  <url name="MolecularType(MEK)">http://identifiers.org/sbo/SBO:0000029</url>
  <url name="MolecularType(MEK)">http://identifiers.org/sbo/SBO:0000012</url>
  <url name="MolecularType(MEK)">http://identifiers.org/sbo/SBO:0000029</url>
  <url name="MolecularType(MEK)">http://identifiers.org/sbo/SBO:0000029</url>
  <url name="MolecularType(MEK)">http://identifiers.org/sbo/SBO:0000029</url>
  <url name="MolecularType(MEK)">http://identifiers.org/sbo/SBO:0000012</url>
  <url name="MolecularType(MEK)">http://identifiers.org/sbo/SBO:0000029</url>
  <url name="MolecularType(MEK)">http://identifiers.org/sbo/SBO:0000029</url>
  <url name="MolecularType(MEK)">http://identifiers.org/sbo/SBO:0000029</url>
  <url name="MolecularType(MEK)">http://identifiers.org/sbo/SBO:0000029</url>
  <url name="MolecularType(MEK)">http://identifiers.org/interpro/IPR020849</url>
  <url name="MolecularType(MEK)">http://identifiers.org/sbo/SBO:0000029</url>
  <url name="MolecularType(MEK)">http://identifiers.org/sbo/SBO:0000001</url>
  <url name="MolecularType(MEK)">http://identifiers.org/sbo/SBO:0000029</url>
  <url name="MolecularType(MEK)">http://identifiers.org/sbo/SBO:0000029</url>
  <url name="MolecularType(MEK)">http://identifiers.org/interpro/IPR020849</url>
  <url name="MolecularType(MEK)">http://identifiers.org/uniprot/P11345</url>
  <url name="MolecularType(MEK)">http://identifiers.org/uniprot/P11345</url>
  <text name="Species(species_26)">    Active species of PP2A; Initial value taken from Brown et al 2004   </text>
  <text name="Species(species_11)"> Inactive species of ERK; Initial value taken from Brown et al 2004  </text>
  <text name="SimulationContext(Deterministic)">      </text>
  <text name="Species(species_8)">    Active species of MEK; Initial value taken from Brown et al 2004   </text>
  <text name="BioModel(CM_PM19804630_MB2::Erk_activation)">     Orton2009 - Modelling cancerous mutations in the EGFR/ERK pathway - EGF Model   This model studies the aberrations in ERK signalling for different cancer mutations. The authors alter a previously existing EGF model (Brown et al 2004) to include new interactions that better fit empirical data. Predictions show that the ERK signalling is a robust mechanism taking different courses for different cancer mutations. Most parameter values are used from the previous model and the new parameters are estimated using experimental data performed by the authors on PC12 cells (adrenal gland, rat). The authors provide an SBML version of the model in the paper.    This model is described in the article:   Computational modelling of cancerous mutations in the EGFR/ERK signalling pathway.   Orton RJ, Adriaens ME, Gormand A, Sturm OE, Kolch W, Gilbert DR.   BMC Syst Biol 2009 Oct; 3: 100   Abstract:    The Epidermal Growth Factor Receptor (EGFR) activated Extracellular-signal Regulated Kinase (ERK) pathway is a critical cell signalling pathway that relays the signal for a cell to proliferate from the plasma membrane to the nucleus. Deregulation of the EGFR/ERK pathway due to alterations affecting the expression or function of a number of pathway components has long been associated with numerous forms of cancer. Under normal conditions, Epidermal Growth Factor (EGF) stimulates a rapid but transient activation of ERK as the signal is rapidly shutdown. Whereas, under cancerous mutation conditions the ERK signal cannot be shutdown and is sustained resulting in the constitutive activation of ERK and continual cell proliferation. In this study, we have used computational modelling techniques to investigate what effects various cancerous alterations have on the signalling flow through the ERK pathway.We have generated a new model of the EGFR activated ERK pathway, which was verified by our own experimental data. We then altered our model to represent various cancerous situations such as Ras, B-Raf and EGFR mutations, as well as EGFR overexpression. Analysis of the models showed that different cancerous situations resulted in different signalling patterns through the ERK pathway, especially when compared to the normal EGF signal pattern. Our model predicts that cancerous EGFR mutation and overexpression signals almost exclusively via the Rap1 pathway, predicting that this pathway is the best target for drugs. Furthermore, our model also highlights the importance of receptor degradation in normal and cancerous EGFR signalling, and suggests that receptor degradation is a key difference between the signalling from the EGF and Nerve Growth Factor (NGF) receptors.Our results suggest that different routes to ERK activation are being utilised in different cancerous situations which therefore has interesting implications for drug selection strategies. We also conducted a comparison of the critical differences between signalling from different growth factor receptors (namely EGFR, mutated EGFR, NGF, and Insulin) with our results suggesting the difference between the systems are large scale and can be attributed to the presence/absence of entire pathways rather than subtle difference in individual rate constants between the system      </text>
  <text name="ReactionStep(Erk_Activation)">    Activation of inactive species Erk as stimulated by MEK. Parameters taken from Brown et al 2004   </text>
  <text name="Structure(cell)">    A common cell line used to investigate ERK signaling from growth factor receptors is the PC12 (rat pheochromocytoma) cell line.   </text>
  <text name="Species(species_10)">    Active species of ERK; Initial value taken from Brown et al 2004   </text>
  <text name="MolecularType(MEK)">      </text>
  <text name="ReactionStep(Erk_Deactivation)">    Deactivation of active species Erk as stimulated by PP2A. Parameters taken from Brown et al 2004   </text>
  <text name="MolecularType(PP2A)">      </text>
</BioModel>
